Sam Afkhami1,2,3, Rocky Lai1,2,3, Michael R D'agostino1,2,3, Maryam Vaseghi-Shanjani1,2,3, Anna Zganiacz1,2,3, Yushi Yao1,2,3, Mangalakumari Jeyanathan1,2,3, Zhou Xing1,2,3. 1. McMaster Immunology Research Center, McMaster University, Hamilton, Ontario, Canada. 2. Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada. 3. Michael G. DeGroote Institute for Infectious Disease Research, McMaster University, Hamilton, Ontario, Canada.
Abstract
BACKGROUND: The development of strategies to accelerate disease resolution and shorten antibiotic therapy is imperative in curbing the global tuberculosis epidemic. Therapeutic application of novel vaccines adjunct to antibiotics represents such a strategy. METHODS: By using a murine model of pulmonary tuberculosis (TB), we have investigated whether a single respiratory mucosal therapeutic delivery of a novel chimpanzee adenovirus-vectored vaccine expressing Ag85A (AdCh68Ag85A) accelerates TB disease control in conjunction with antibiotics and restricts pulmonary disease rebound after premature (nonsterilizing) antibiotic cessation. RESULTS: We find that immunotherapy via the respiratory mucosal, but not parenteral, route significantly accelerates pulmonary mycobacterial clearance, limits lung pathology, and restricts disease rebound after premature antibiotic cessation. We further show that vaccine-activated antigen-specific T cells, particularly CD8 T cells, in the lung play an important role in immunotherapeutic effects. CONCLUSIONS: Our results indicate that a single-dose respiratory mucosal immunotherapy with AdCh68Ag85A adjunct to antibiotic therapy has the potential to significantly accelerate disease control and shorten the duration of conventional treatment. Our study provides the proof of principle to support therapeutic applications of viral-vectored vaccines via the respiratory route.
BACKGROUND: The development of strategies to accelerate disease resolution and shorten antibiotic therapy is imperative in curbing the global tuberculosis epidemic. Therapeutic application of novel vaccines adjunct to antibiotics represents such a strategy. METHODS: By using a murine model of pulmonary tuberculosis (TB), we have investigated whether a single respiratory mucosal therapeutic delivery of a novel chimpanzee adenovirus-vectored vaccine expressing Ag85A (AdCh68Ag85A) accelerates TB disease control in conjunction with antibiotics and restricts pulmonary disease rebound after premature (nonsterilizing) antibiotic cessation. RESULTS: We find that immunotherapy via the respiratory mucosal, but not parenteral, route significantly accelerates pulmonary mycobacterial clearance, limits lung pathology, and restricts disease rebound after premature antibiotic cessation. We further show that vaccine-activated antigen-specific T cells, particularly CD8 T cells, in the lung play an important role in immunotherapeutic effects. CONCLUSIONS: Our results indicate that a single-dose respiratory mucosal immunotherapy with AdCh68Ag85A adjunct to antibiotic therapy has the potential to significantly accelerate disease control and shorten the duration of conventional treatment. Our study provides the proof of principle to support therapeutic applications of viral-vectored vaccines via the respiratory route.
Authors: Michael Santosuosso; Sarah McCormick; Elizabeth Roediger; Xizhong Zhang; Anna Zganiacz; Brian D Lichty; Zhou Xing Journal: J Immunol Date: 2007-02-15 Impact factor: 5.422
Authors: Jun Wang; Lisa Thorson; Richard W Stokes; Michael Santosuosso; Kris Huygen; Anna Zganiacz; Mary Hitt; Zhou Xing Journal: J Immunol Date: 2004-11-15 Impact factor: 5.422
Authors: Nilu P Goonetilleke; Helen McShane; Carolyn M Hannan; Richard J Anderson; Roger H Brookes; Adrian V S Hill Journal: J Immunol Date: 2003-08-01 Impact factor: 5.422
Authors: Jennifer L Taylor; Oliver C Turner; Randall J Basaraba; John T Belisle; Kris Huygen; Ian M Orme Journal: Infect Immun Date: 2003-04 Impact factor: 3.441
Authors: Emily K Forbes; Clare Sander; Edward O Ronan; Helen McShane; Adrian V S Hill; Peter C L Beverley; Elma Z Tchilian Journal: J Immunol Date: 2008-10-01 Impact factor: 5.422
Authors: Salla A Munro; Simon A Lewin; Helen J Smith; Mark E Engel; Atle Fretheim; Jimmy Volmink Journal: PLoS Med Date: 2007-07-24 Impact factor: 11.069
Authors: Sam Afkhami; Anne Drumond Villela; Michael R D'Agostino; Mangalakumari Jeyanathan; Amy Gillgrass; Zhou Xing Journal: Front Immunol Date: 2020-09-09 Impact factor: 7.561